

DLST Antibody (C-term) Blocking Peptide Synthetic peptide Catalog # BP2899b

Specification

DLST Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>P36957</u>

DLST Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 1743

Other Names

Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial, 2-oxoglutarate dehydrogenase complex component E2, OGDC-E2, Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex, E2K, DLST, DLTS

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP2899b was selected from the C-term region of human DLST. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

DLST Antibody (C-term) Blocking Peptide - Protein Information

Name DLST (HGNC:2911)

Synonyms DLTS

Function

Dihydrolipoamide succinyltransferase (E2) component of the 2- oxoglutarate dehydrogenase complex. The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl- CoA and CO(2). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711, PubMed:30929736). A fraction of the 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711, PubMed:30929736). A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A



on chromatin and provides succinyl-CoA to histone succinyltransferase KAT2A (PubMed:29211711).

Cellular Location

Mitochondrion matrix. Nucleus Note=Mainly localizes in the mitochondrion. A small fraction localizes to the nucleus, where the 2-oxoglutarate dehydrogenase complex is required for histone succinylation.

DLST Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

DLST Antibody (C-term) Blocking Peptide - Images

DLST Antibody (C-term) Blocking Peptide - Background

DLST catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO2. It contains multiple copies of 3 enzymatic components: 2-oxoglutarate dehydrogenase (E1), dihydrolipoamide succinyltransferase (E2) and lipoamide dehydrogenase (E3).

DLST Antibody (C-term) Blocking Peptide - References

Tu,L.C., et.al., Mol. Cell Proteomics 6 (4), 575-588 (2007)